Document is current
Any future updates will be listed below
-
Authors
Dimopoulos, Marios-Platon
Sotirchos, Vlasios S.
Dunne-Jaffe, Cynthia
Mitchell, Ashara
Petre, Elena N.
Alexander, Erica S.
Gonen, Mithat
Rao, Devika
Connell, Louise C.
Soares, Kevin
Katsanos, Konstantinos
Sofocleous, Constantinos T. https://orcid.org/0000-0002-3142-1399
-
Funding
Funding for this research was provided by:
NIH/NCI (NIH/NCI Cancer Center Support Grant P30 CA008748)
Memorial Sloan-Kettering Cancer Center (Imaging)
Memorial Sloan-Kettering Cancer Center (Radiation Sciences Program)
Sirtex Inc.
Boston Scientific Corporation
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 13 August 2025
First Online: 9 September 2025
Declarations
:
: Constantinos T. Sofocleous receives research support from SIRTEX Medical, Boston Scientific, Ethicon Inc./ NeuWave, Varian Medical Systems; declares consultancy/advisory boards: -J&J/Ethicon, Inc., -Terumo Medical Corporation, -BTG Specialty Pharmaceuticals/Boston Scientific, -SIRTEX Medical, -Varian Medical Systems. No other potential conflicts of interest relevant to this article exist.
: Institutional Review Board waiver of approval was obtained for this retrospective analysis of a prospectively established and maintained HIPAA-compliant clinical database of TARE of CLM. The study encompassed patients with CLM treated with TARE between 9/15/2009 and 7/7/2023.
: Informed consent was obtained from all subjects involved in the study.
: Not applicable.
